Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Co-amilofruse

Co-amilofruse
In stock
5mg
from 22,93 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
27,52 £22,93 £
0,23 £ per tablet

In brief

  • In our pharmacy, you can buy co-amilofruse without a prescription, with delivery in 9–21 days throughout the United Kingdom and discreet packaging.
  • Co-amilofruse is used to treat fluid overload such as peripheral oedema and heart failure; it combines furosemide (a loop diuretic that inhibits the Na+-K+-2Cl− transporter in the thick ascending limb of Henle, causing natriuresis and diuresis) with amiloride (a potassium-sparing diuretic that blocks epithelial sodium channels in the distal nephron to reduce potassium loss).
  • The usual dose is one tablet (40 mg furosemide + 5 mg amiloride) in the morning; this may be increased to one tablet twice daily if required, with a maximum of four tablets per day (maximum amiloride 20 mg/day) under medical supervision.
  • The form of administration is an oral tablet (scored for splitting; orange and typically marked on the tablet for brand variants).
  • The effect usually begins within 30–60 minutes after an oral dose.
  • The diuretic effect typically lasts about 6–8 hours; the potassium-sparing action may persist longer.
  • Avoid excessive alcohol while taking co-amilofruse, as alcohol can increase the risk of dizziness, fainting and dehydration and may worsen low blood pressure.
  • The most common side effect is increased urination; other frequent effects include dizziness (especially on standing), electrolyte disturbances (eg low sodium or potassium), mild dehydration and gastrointestinal upset.
  • Would you like to try co-amilofruse without a prescription?

Basic co-amilofruse information

  • INN (international nonproprietary name): furosemide (frusemide) and amiloride hydrochloride.
  • Brand names available in the United Kingdom: Frumil 40mg/5mg; generic co-amilofruse tablets.
  • ATC code: C03EB01.
  • Forms and dosages: Tablet — 40 mg furosemide + 5 mg amiloride; oral, scored for splitting.
  • Manufacturers in the United Kingdom: Sanofi (originator) and generic manufacturers.
  • Registration status in the United Kingdom: Licensed as a prescription-only medicine (POM) with PIL and SPC available online.
  • OTC / Rx classification: Prescription only medicine (POM) in the UK.

Critical warnings and restrictions

High-risk groups — elderly, pregnancy, chronic illness

If you are elderly, pregnant, breastfeeding or have a long-term medical condition you need extra safeguards before starting co-amilofruse.

  • Immediate safety priorities: stop or withhold co-amilofruse and seek urgent medical review if you develop severe dehydration, marked dizziness or fainting, signs of marked electrolyte disturbance or anuria.
  • Monitor serum electrolytes (potassium, sodium), renal function and blood pressure at baseline, after dose changes and periodically thereafter.
  • Pregnancy and breastfeeding: avoid unless a specialist has advised it after considering risks and benefits.

Absolute contraindications (checklist)

  • Anuria or severe renal failure.
  • Hyperkalaemia.
  • Addison’s disease.
  • Known allergy to furosemide, amiloride, sulfonamides or related compounds.
  • Pregnancy and breastfeeding unless specialist advises.

Monitoring

  • Baseline and periodic blood tests: serum potassium, sodium and renal function (creatinine/eGFR).
  • Blood pressure checks at baseline and after dose changes.
  • Weight and fluid-balance monitoring.
  • Medication review for interacting drugs, especially ACE inhibitors/ARBs, NSAIDs and lithium.

Dispensing note (checklist)

  • POM status: supply only with a valid prescription as per MHRA classification.
  • Counsel patients on increased urination and the best timing for doses (typically morning).
  • Advise orthostatic precautions: rise slowly from lying/sitting positions to reduce fainting risk.

Q&A — “Can I drive after taking it in the UK?”

  • Short answer: usually yes, but only if you feel well and free of dizziness or lightheadedness.
  • If you experience dizziness, blurred vision, fainting or orthostatic hypotension you must not drive or operate machinery.
  • Report adverse effects via the Yellow Card system and follow DVLA guidance if symptoms persist.

Usage basics

INN, brand names available in the UK

  • Active ingredients: furosemide (also written frusemide) and amiloride hydrochloride.
  • Common UK brand: Frumil 40mg/5mg; generics labelled as furosemide + amiloride are also seen.
  • Tablet appearance: orange, scored, marked “FRUMIL” and supplied in blister packs or bottles — always check packaging for both actives.
INN
The international nonproprietary names for the active substances: furosemide and amiloride hydrochloride.
Brand
The trade name used by the manufacturer, commonly Frumil 40mg/5mg in the UK.

Legal classification

  • Classification: Prescription-only medicine (POM) regulated by the MHRA in the United Kingdom.
  • Patient information leaflets (PIL) and the summary of product characteristics (SPC) are available online for prescribers and pharmacists.

Dosing guide

Standard regimens — NHS-style advice

  • Typical adult starting dose: 1 tablet (40 mg furosemide / 5 mg amiloride) once daily in the morning.
  • Adjustment: may be increased to 2 tablets per day, taken AM and at noon, if required under clinical supervision.
  • Maximum amiloride dose: 20 mg per day (equivalent to 4 tablets); follow specialist direction for higher needs.

Adjustments for comorbidities

  • Elderly: start at the lowest effective dose and titrate cautiously due to increased sensitivity and comorbidities.
  • Renal impairment: contraindicated in severe renal failure and anuria; in mild–moderate impairment use with caution and close electrolyte monitoring.
  • Liver disease: use cautiously because of encephalopathy risk; adjust dose under specialist advice.
Suggested dosing Split/tablet guidance Monitoring schedule
Start 1 tablet once daily (AM) Tablet scored — may be halved if clinician advises lower dose Baseline blood tests then re-check within 1–2 weeks after initiation or dose change
Increase to 1 tablet AM and 1 tablet noon if needed Avoid evening doses to reduce nocturia Regular checks every 1–3 months depending on renal function and comedications

Q&A — “What if I miss a dose?”

  • Take the missed dose as soon as you remember unless it is close to the next dose.
  • Do not double up doses to make up for a missed tablet.
  • If unsure, contact your GP or pharmacist for advice.

Interaction chart

Food and drinks

  • Alcohol may increase dizziness and worsen blood-pressure falls; advise limiting alcohol while taking co-amilofruse.
  • There are no strong dietary interactions, but maintain consistent potassium intake and seek advice before using salt substitutes.

Common drug conflicts

Interacting drug/class Risk Action/monitoring
ACE inhibitors / ARBs Risk of hyperkalaemia when combined with potassium-sparing diuretics Check potassium and renal function soon after co-prescribing
Potassium supplements / other K-sparing diuretics Hyperkalaemia risk Avoid unless closely monitored; check serum potassium
NSAIDs Reduced diuretic effect and increased renal risk Review need for NSAID; monitor renal function
Lithium Increased lithium toxicity risk Frequent lithium level checks and liaison with prescriber
Aminoglycosides Increased ototoxicity risk with loop diuretics Avoid combination where possible; monitor auditory symptoms
Digoxin Arrhythmia risk if electrolytes change (especially potassium) Monitor ECG and potassium levels

Monitoring prompts (checklist)

  • Baseline blood tests for electrolytes and renal function before starting interacting medicines.
  • Early re-checks after starting or changing doses of interacting drugs.
  • Report suspected interactions or adverse reactions via the Yellow Card scheme.

Legal status and availability in the UK

Co-amilofruse is a prescription-only medicine (POM) in the UK.

In our online pharmacy, co-amilofruse is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Furosemide is a loop diuretic that increases excretion of sodium and water through action in the thick ascending limb of the loop of Henle.

Amiloride is a potassium-sparing diuretic that acts on the collecting duct to reduce potassium loss.

The combination aims to relieve fluid overload while reducing the risk of hypokalaemia compared with loop diuretic alone.

Clinical terms

ATC classification
C03EB01 — combination of potassium-sparing and other diuretics.
Loop diuretic
A medication that acts on the loop of Henle to promote water and sodium excretion.
Potassium-sparing
Drugs that reduce urinary potassium loss at the distal nephron.
SPC vs PIL
The summary of product characteristics (SPC) is for professionals; the patient information leaflet (PIL) is written for patients.
Nephron site Primary pharmacodynamic effect
Thick ascending limb (loop of Henle) Furosemide: increased Na+/Cl-/water excretion
Collecting duct Amiloride: reduced K+ secretion; potassium conservation

Indications and off-label uses

MHRA-approved uses

  • Licensed for management of oedema and fluid retention due to heart failure and other causes where a loop diuretic with potassium conservation is indicated.
  • Not licensed as a first-line monotherapy for hypertension.

Off-label practices in NHS and private care

  • Occasionally used off-label in specialist settings for resistant oedema or when hypokalaemia risk must be minimised.
  • Off-label use should be documented, patient consented and monitoring arranged.

Prescriber justification checklist

  • Document clinical indication and reasons for choosing the combination over alternatives.
  • Provide patient information about monitoring, potential risks and follow-up plans.
  • Arrange baseline and follow-up blood tests when prescribing off-label.

Alternatives matrix

NHS prescribing alternatives

Drug Mechanism Typical use Key monitoring Pros Cons
Furosemide alone Loop diuretic Rapid diuresis for oedema Electrolytes, renal function Strong diuretic effect Risk of hypokalaemia
Co-amilozide (amiloride + hydrochlorothiazide) Potassium-sparing + thiazide Oedema, hypertension in some cases Electrolytes, BP Conserves potassium vs thiazide alone Different sodium handling vs loop diuretics
Spironolactone combinations Aldosterone antagonist ± thiazide Heart failure, resistant oedema Electrolytes, renal function Useful where aldosterone plays a role Hyperkalaemia risk, endocrine side effects

Pros and cons checklist for alternatives

  • Consider efficacy for oedema versus potassium effects (hypo- versus hyperkalaemia).
  • Account for renal monitoring needs and blood-pressure effects.
  • Consider local formulary preferences.

Common questions (patient FAQs)

  • Will it make me pass a lot of urine? — Yes; most patients see increased urine output soon after starting; take in the morning to limit nocturia.
  • How often will I need blood tests? — Baseline tests and early re-check after initiation or dose change; frequency depends on renal function and co-medications.
  • Can I take potassium supplements or salt substitutes? — Not without clinician advice because amiloride can raise potassium levels.
  • How do I report side effects? — Report via the MHRA Yellow Card scheme or discuss with your GP or pharmacist.

Registration and regulation

MHRA approval process

  • Co-amilofruse is licensed as a prescription-only medicine (POM) by the MHRA in the UK.
  • The SPC and PIL should be consulted by prescribers and pharmacists for up-to-date product details.

NHS prescribing framework

  • Follow local formulary guidance when prescribing; pharmacists should confirm indication and monitoring obligations.
  • Report suspected adverse drug reactions (ADRs) via the Yellow Card scheme and keep accurate records for audit.

Licence, SPC consultation and reporting routes:

  • Licence issued by MHRA.
  • Consult SPC and PIL for product details.
  • Report ADRs via Yellow Card and document in patient record.

Storage and handling

UK household storage — damp/cold climate

  • Store below 25°C and protect from moisture and direct light.
  • Keep tablets in their original blister pack or bottle and out of reach of children.
  • Do not store in the bathroom or on a windowsill where damp or heat may affect stability.

Pharmacy transport and disposal

  • Standard ambient transport is acceptable; follow the handling instructions on the pack.
  • Return unused medicines to a pharmacy for safe disposal per NHS guidance.

Practical household checklist

  • Check expiry dates before use.
  • Keep with dosing reminders or a calendar if multiple medicines are taken.
  • Store away from damp and direct sunlight.

Guidelines for proper use

UK pharmacist counselling style

  • Confirm the indication and why co-amilofruse was chosen for the patient.
  • Explain expected diuretic effect and recommend morning dosing to reduce nocturia.
  • Discuss orthostatic precautions and warn about signs of electrolyte disturbance such as muscle weakness or palpitations.
  • Ask about pregnancy and breastfeeding status before supply.
  • Advise not to stop the medicine suddenly without review.

NHS patient safety advice

  • Encourage patients to carry a list of current medicines and to ensure GP follow-up for blood tests.
  • Document weight changes, urine output and blood test results in primary care records for ongoing review.
  • Report side effects via the Yellow Card and seek urgent care for severe dehydration or fainting.

Delivery across the United Kingdom

City Region Delivery time
London England 9–21 days
Birmingham England 9–21 days
Manchester England 9–21 days
Glasgow Scotland 9–21 days
Liverpool England 9–21 days
Leeds England 9–21 days
Bristol England 9–21 days
Edinburgh Scotland 9–21 days
Cardiff Wales 9–21 days
Belfast Northern Ireland 9–21 days
Sheffield England 9–21 days
Newcastle England 9–21 days
Nottingham England 9–21 days

Related products